Andrew Briggs
Auto-generated profile, based on publicly available information

Andrew Briggs

Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Value in Health
Verified
Journal Article
Closed access
DHDon Husereau
Don Husereau
MDMichael Drummond
Michael Drummond
Stavros PetrouStavros Petrou
Stavros Petrou
CCChris Carswell
Chris Carswell
DMDavid Moher
David Moher
ELElizabeth Loder
Elizabeth Loder

25 March 2013 in BMJ
Verified
Journal Article
Open access
PDF file
DHDon Husereau
Don Husereau
MDMichael Drummond
Michael Drummond
Stavros PetrouStavros Petrou
Stavros Petrou
CCChris Carswell
Chris Carswell
DMDavid Moher
David Moher
OFOn Behalf Of The Cheers Task Force
On Behalf Of The Cheers Task Force
Economic evaluations of health interventions pose a particular challenge for reporting. There is also a need to consolidate and update existing guidelines and promote their use in a user friendly manner. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement is an attempt to consolidate and update previous health economic evaluation guidelines efforts into one current, useful reporting guidance. The primary audiences for the CHEERS statement are researchers reporting economic evaluations and the editors and peer reviewers assessing them for publication. The need for new reporting guidance was identified by a survey of medical editors. A list of possible items based on a systematic review was created. A two round, modified Delphi panel consisting of representatives from academia, clinical practice, industry, government, and the editorial community was conducted. Out of 44 candidate items, 24 items and accompanying recommendations were developed. The recommendations are contained in a user friendly, 24 item checklist. A copy of the statement, accompanying checklist, and this report can be found on the ISPOR Health Economic Evaluations Publication Guidelines Task Force website (www.ispor.org/TaskForces/EconomicPubGuidelines.asp). We hope CHEERS will lead to better reporting, and ultimately, better health decisions. To facilitate dissemination and uptake, the CHEERS statement is being co-published across 10 health economics and medical journals. We encourage other journals and groups, to endorse CHEERS. The author team plans to review the checklist for an update in five years.

31 January 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HLHo-Kwong Li
Ho-Kwong Li
IRInes Rombach
Ines Rombach
RZRhea Zambellas
Rhea Zambellas
AWA. Sarah Walker
A. Sarah Walker
MMMartin A. McNally
Martin A. McNally
MSMatthew Scarborough
Matthew Scarborough
The management of complex orthopedic infections usually includes a prolonged course of intravenous antibiotic agents. We investigated whether oral antibiotic therapy is noninferior to intravenous antibiotic therapy for this indication. We enrolled adults who were being treated for bone or joint infection at 26 U.K. centers. Within 7 days after surgery (or, if the infection was being managed without surgery, within 7 days after the start of antibiotic treatment), participants were randomly assigned to receive either intravenous or oral antibiotics to complete the first 6 weeks of therapy. Follow-on oral antibiotics were permitted in both groups. The primary end point was definitive treatment failure within 1 year after randomization. In the analysis of the risk of the primary end point, the noninferiority margin was 7.5 percentage points. Among the 1054 participants (527 in each group), end-point data were available for 1015 (96.3%). Treatment failure occurred in 74 of 506 participants (14.6%) in the intravenous group and 67 of 509 participants (13.2%) in the oral group. Missing end-point data (39 participants, 3.7%) were imputed. The intention-to-treat analysis showed a difference in the risk of definitive treatment failure (oral group vs. intravenous group) of −1.4 percentage points (90% confidence interval [CI], −4.9 to 2.2; 95% CI, −5.6 to 2.9), indicating noninferiority. Complete-case, per-protocol, and sensitivity analyses supported this result. The between-group difference in the incidence of serious adverse events was not significant (146 of 527 participants [27.7%] in the intravenous group and 138 of 527 [26.2%] in the oral group; P=0.58). Catheter complications, analyzed as a secondary end point, were more common in the intravenous group (9.4% vs. 1.0%). Oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first 6 weeks for complex orthopedic infection, as assessed by treatment failure at 1 year. (Funded by the National Institute for Health Research; OVIVA Current Controlled Trials number, ISRCTN91566927.)

18 September 2012 in Medical Decision Making
Verified
Journal Article
Open access
PDF file
ABAndrew H. Briggs
Andrew H. Briggs
MWMilton C. Weinstein
Milton C. Weinstein
EFElisabeth A. L. Fenwick
Elisabeth A. L. Fenwick
JKJonathan Karnon
Jonathan Karnon
MSMark J. Sculpher
Mark J. Sculpher
APA. David Paltiel
A. David Paltiel
A model’s purpose is to inform medical decisions and health care resource allocation. Modelers employ quantitative methods to structure the clinical, epidemiological, and economic evidence base and gain qualitative insight to assist decision makers in making better decisions. From a policy perspective, the value of a model-based analysis lies not simply in its ability to generate a precise point estimate for a specific outcome but also in the systematic examination and responsible reporting of uncertainty surrounding this outcome and the ultimate decision being addressed. Different concepts relating to uncertainty in decision modeling are explored. Stochastic (first-order) uncertainty is distinguished from both parameter (second-order) uncertainty and from heterogeneity, with structural uncertainty relating to the model itself forming another level of uncertainty to consider. The article argues that the estimation of point estimates and uncertainty in parameters is part of a single process and explores the link between parameter uncertainty through to decision uncertainty and the relationship to value-of-information analysis. The article also makes extensive recommendations around the reporting of uncertainty, both in terms of deterministic sensitivity analysis techniques and probabilistic methods. Expected value of perfect information is argued to be the most appropriate presentational technique, alongside cost-effectiveness acceptability curves, for representing decision uncertainty from probabilistic analysis.

5 February 2013 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
RRRichard D. Riley
Richard D. Riley
JHJill A. Hayden
Jill A. Hayden
ESEwout W. Steyerberg
Ewout W. Steyerberg
KMKarel G. M. Moons
Karel G. M. Moons
KAKeith Abrams
Keith Abrams
HHHarry Hemingway
Harry Hemingway
In the second article in the PROGRESS series on prognostic factor research, Sara Schroter and colleagues discuss the role of prognostic factors in current clinical practice, randomised trials, and developing new interventions, and explain why and how prognostic factor research should be improved.

1 March 2015 in Value in Health
Verified
Journal Article
Closed access
SRScott D. Ramsey
Scott D. Ramsey
RWRichard J. Willke
Richard J. Willke
HGHenry Glick
Henry Glick
SRShelby D. Reed
Shelby D. Reed
FAFederico Augustovski
Federico Augustovski
SSSean D. Sullivan
Sean D. Sullivan